nilotinib pharmacokinetics correlation with clinical response and adverse events in chronic myelogenous leukemia

nilotinib pharmacokinetics correlation with clinical response and adverse events in chronic myelogenous leukemia - nilotinib pahrmacokinetics in Japanese CML patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002895

Enrollment

Registered

2009-12-14

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myelogenous leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Chronic myelogenous leukemia in chronic-phase and accerated-phase. 2.Age =>20 year 3.PS 0-2(ECOG) 4.No severe major organ dysfunction (AST,ALT, creatinine <3.0x ULN) 5.Written informed consent

Exclusion criteria

Exclusion criteria: 1.Patients suspected in blast crisis 2.History of a invasive double cancer within 5 years before 3.Pregnant and/or lactating woman 4.Severe psychological disorders 5.Uncontorlled complications

Design outcomes

Primary

Measure	Time frame
nilotinib pahrmacokinetics in Japanese CML patients	—

Secondary

Measure	Time frame
clinical response adverse events	—

Countries

Japan

Contacts

Public ContactMasaya Okada

hyogo college of medicine Division of Hematology, Department of Internal Medicine

masaya@hyo-med.ac.jp0798-45-6886

Outcome results